EA
CBIO

Emerald Acquisition’s Crescent Biopharma CBIO Stock Holding History

Emerald Acquisition’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$51K Buy
+71
New +$54.3K ﹤0.01% 2886

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Emerald Acquisition's CBIO Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Crescent Biopharma (CBIO) in Q3 2016: 71 shares worth $51K. The stake represents ﹤0.01% of the portfolio and ranks #2886 among its holdings.

48 funds tracked by Wall St. Rank hold CBIO as of Q3 2016.

  • Emerald Acquisition held 71 shares of Crescent Biopharma worth $51K as of Q3 2016.
  • Crescent Biopharma was a new Emerald Acquisition position in Q3 2016.
  • Crescent Biopharma made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2886 holding.
  • 48 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.